|
References
|
Definition of tumor-cell positivity
|
Detection method
|
Target gene/antigen
|
Follow-up (months)
|
Outcomes reported
|
stage
|
Multivariate analysis
|
|---|
|
Median
|
Range
|
|---|
|
Chun-Dong Gu
|
LNMM
|
IHC
|
CK(AbAE1/A)
|
44
|
4 –60
|
OS
|
I
|
Yes
|
|
Kazuhito Dobashi
|
LNMM
|
IHC
|
CK(AbAE1/A)
|
13.6
|
1-60
|
OS
|
pN0
|
Yes
|
|
B. Passlick
|
LNMM
|
IHC
|
CK
|
NR
|
NR
|
OS
|
pN0
|
Yes
|
|
Jakob R. Izbicki,
|
LNMM
|
IHC/FCM
|
Ber-Ep-4
|
NR
|
3-40
|
DFS
|
pN0
|
Yes
|
|
By Toshihiro Osaki
|
LNMM
|
IHC
|
CK(AbAE1/A)
|
35.8
|
0.1-90.6
|
OS
|
I
|
Yes
|
|
Kosei Yasumoto
|
LNMM
|
IHC
|
CK2
|
48.2
|
1-64
|
OS/DFS
|
I
|
Yes
|
|
Valerie W. Rusch
|
LNMM
|
IHC
|
CK(AE-1)
|
NR
|
0-60
|
OS/DFS
|
pN0
|
Yes
|
|
Wang Zhou
|
LNMM
|
RT-PCR
|
MUC1
|
NR
|
0-36
|
OS
|
pN0
|
Yes
|
- Abbreviations: LMMM lymph node micrometastases, IHC immunohistochemistry, CK cytokeratin, DFS disease- free survival, OS overall survival, NR not reported, RT-PCR Reverse transcription-polymerase chain reaction. MUC1, polymorphic epithelial mucin 1
